Lataa...
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
Cemiplimab, a human monoclonal antibody targeting programmed cell death-1 (PD-1) receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety profile comparable to other anti–PD-1 therapies. This population pharmacokinetics (PopPK) analysis of cemiplimab included 11,...
Tallennettuna:
| Julkaisussa: | J Pharmacokinet Pharmacodyn |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer US
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8225544/ https://ncbi.nlm.nih.gov/pubmed/33728546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10928-021-09739-y |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|